Malini Raghavan
Overview
Explore the profile of Malini Raghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaur A, Venkatesan A, Kandarpa M, Talpaz M, Raghavan M
Blood Adv
. 2024 Apr;
8(13):3372-3387.
PMID: 38640435
Somatic mutants of calreticulin (CRT) drive myeloproliferative neoplasms (MPNs) via binding to the thrombopoietin receptor (MPL) and aberrant activation of the JAK/STAT pathway. Compared with healthy donors, platelets from mutant...
2.
Jiang C, Zhao L, Green M, Ravishankar S, Towlerton A, Scott A, et al.
Sci Rep
. 2024 Jan;
14(1):345.
PMID: 38172168
Immune checkpoint inhibitors (ICI) are important treatment options for metastatic non-small cell lung cancer (mNSCLC). However, not all patients benefit from ICIs and can experience immune-related adverse events (irAEs). Limited...
3.
Kaur A, Surnilla A, Zaitouna A, Mumphrey M, Basrur V, Grigorova I, et al.
J Immunol
. 2023 Sep;
211(9):1298-1307.
PMID: 37737643
The extreme polymorphisms of HLA class I proteins result in structural variations in their peptide binding sites to achieve diversity in Ag presentation. External factors could independently constrict or alter...
4.
Pogozheva I, Cherepanov S, Park S, Raghavan M, Im W, Lomize A
J Chem Inf Model
. 2023 Sep;
63(18):5874-5895.
PMID: 37694948
Homodimeric class 1 cytokine receptors include the erythropoietin (EPOR), thrombopoietin (TPOR), granulocyte colony-stimulating factor 3 (CSF3R), growth hormone (GHR), and prolactin receptors (PRLR). These cell-surface single-pass transmembrane (TM) glycoproteins regulate...
5.
Mumphrey M, Hosseini N, Parolia A, Geng J, Zou W, Raghavan M, et al.
Cell Rep
. 2023 Aug;
42(8):112965.
PMID: 37597185
Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the...
6.
Pogozheva I, Cherepanov S, Park S, Raghavan M, Im W, Lomize A
bioRxiv
. 2023 Jul;
PMID: 37398331
Homodimeric class 1 cytokine receptors include the erythropoietin (EPOR), thrombopoietin (TPOR), granulocyte colony-stimulating factor 3 (CSF3R), growth hormone (GHR), and prolactin receptors (PRLR). They are cell-surface single-pass transmembrane (TM) glycoproteins...
7.
Olson E, Raghavan M
Curr Opin Immunol
. 2023 Jun;
84:102356.
PMID: 37379719
Major histocompatibility complex class I (MHC class I) molecules facilitate subcellular immune surveillance by presenting peptides on the cell surface. MHC class I assembly with peptides generally happens in the...
8.
Desikan H, Kaur A, Pogozheva I, Raghavan M
J Cell Mol Med
. 2023 Mar;
27(8):1032-1044.
PMID: 36916035
Myeloproliferative neoplasms (MPNs) are cancers involving dysregulated production and function of myeloid lineage hematopoietic cells. Among MPNs, Essential thrombocythemia (ET), Polycythemia Vera (PV) and Myelofibrosis (MF), are driven by mutations...
9.
Kaur A, Surnilla A, Zaitouna A, Basrur V, Mumphrey M, Grigorova I, et al.
bioRxiv
. 2023 Mar;
PMID: 36909546
Activation of CD8 T cells against pathogens and cancers involves the recognition of antigenic peptides bound to human leukocyte antigen (HLA) class-I proteins. Peptide binding to HLA class I proteins...
10.
Olson E, Ceccarelli T, Raghavan M
Elife
. 2023 Feb;
12.
PMID: 36722462
The extreme polymorphisms of human leukocyte antigen class I (HLA class I) proteins enable the presentation of diverse peptides to cytotoxic T lymphocytes. The canonical endoplasmic reticulum (ER) HLA class...